ATE300611T1 - Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen - Google Patents

Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen

Info

Publication number
ATE300611T1
ATE300611T1 AT01960237T AT01960237T ATE300611T1 AT E300611 T1 ATE300611 T1 AT E300611T1 AT 01960237 T AT01960237 T AT 01960237T AT 01960237 T AT01960237 T AT 01960237T AT E300611 T1 ATE300611 T1 AT E300611T1
Authority
AT
Austria
Prior art keywords
receptor
binding
screening methods
protein interactions
based screening
Prior art date
Application number
AT01960237T
Other languages
English (en)
Inventor
Sven Eyckerman
Ostade Xaveer Van
Joel Vandekerckhove
Annick Verhee
Jan Tavernier
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE300611T1 publication Critical patent/ATE300611T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/90Fusion polypeptide containing a motif for post-translational modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/06Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT01960237T 2000-05-22 2001-05-22 Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen ATE300611T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201771 2000-05-22
PCT/EP2001/005916 WO2001090188A2 (en) 2000-05-22 2001-05-22 Receptor-based interaction trap

Publications (1)

Publication Number Publication Date
ATE300611T1 true ATE300611T1 (de) 2005-08-15

Family

ID=8171515

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01960237T ATE300611T1 (de) 2000-05-22 2001-05-22 Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen

Country Status (8)

Country Link
US (2) US7855270B2 (de)
EP (2) EP1612221A3 (de)
JP (1) JP4756813B2 (de)
AT (1) ATE300611T1 (de)
AU (2) AU2001281784B2 (de)
CA (1) CA2407872C (de)
DE (1) DE60112282T2 (de)
WO (1) WO2001090188A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
WO2003004643A2 (en) 2001-07-03 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Reversed mammalian protein-protein interaction trap
GB201103453D0 (en) 2011-03-01 2011-04-13 Vib Vzw Kinase substrate sensor
US9746470B2 (en) * 2011-05-09 2017-08-29 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
EP2823044B1 (de) 2012-03-06 2017-12-06 VIB vzw Membran-spankinase-fusionsprotein und verwendungen davon
WO2013174999A1 (en) 2012-05-24 2013-11-28 Vib Vzw Virus-like particle based protein-protein interaction
GB201504859D0 (en) 2015-03-23 2015-05-06 Vib Vzw Viral particle based small molecule-protein interaction trap
GB201909491D0 (en) * 2019-07-01 2019-08-14 Governing Council Of The Univ Of Toronto Detection of protein to protein interactions
CN115210381A (zh) * 2019-12-17 2022-10-18 奥里尼斯生物科学股份有限公司 新型降解相关相互作用的检测
AU2020404918A1 (en) * 2019-12-17 2022-07-07 Orionis Biosciences BV Detection of molecular interactions
AU2022349077A1 (en) * 2021-09-22 2024-03-28 Sonoma Biotherapeutics, Inc. Il5ra cell surface markers

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892296A1 (de) 1988-09-02 2008-02-27 Dyax Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CZ206195A3 (en) 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
US5521066A (en) * 1993-09-13 1996-05-28 Bristol-Myers Squibb Company Periplasmic membrane-bound system for detecting protein-protein interactions
US5935797A (en) * 1994-06-16 1999-08-10 Stanford University Interaction of MHC Class II proteins with members of the PCNA family of proteins
US5716622A (en) * 1995-01-06 1998-02-10 The Rockefeller University Functionally active regions of signal transducer and activators of transcription
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5637463A (en) 1995-05-04 1997-06-10 Hoffmann-La Roche Inc. Method to detect protein-protein interactions
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
SE9503151D0 (sv) 1995-09-13 1995-09-13 Bioinvent Internatioal Ab Combined ligand and receptor display
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
AU1406497A (en) 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
EP0882128A1 (de) * 1996-02-23 1998-12-09 Ariad Pharmaceuticals, Inc. Auf zellen basierendes testverfahren
EP0883686A1 (de) 1996-02-26 1998-12-16 Morphosys Gesellschaft für Proteinoptimierung mbH Methode zur identifikation von nukleinsäuren für zwei oder mehreren interagierenden (poly)peptiden
CA2257240A1 (en) 1996-06-06 1997-12-11 Smithkline Beecham P.L.C. Fragments of leptin (ob protein)
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US5843697A (en) * 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5776689A (en) * 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
CN1230966A (zh) 1996-09-20 1999-10-06 赫彻斯特股份公司 勒帕素拮抗剂在用于治疗ii型糖尿病胰岛素耐受性中的用途
EP0951564A1 (de) 1996-11-01 1999-10-27 Smithkline Beecham Plc Verfahren zum nachweis zur modulation der effekte vom obesitäts-(ob)-protein
CA2196496A1 (en) * 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US6342345B1 (en) * 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
AU8405998A (en) * 1997-07-15 1999-02-10 Aurora Biosciences Corporation Compositions and methods for identifying modulators of transducisomes, a ew class of therapeutic targets
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
CA2320226A1 (en) 1998-02-11 1999-08-19 Beth Israel Deaconess Medical Center Methods and compositions for modulating leptin activity
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
JP2002522031A (ja) * 1998-07-28 2002-07-23 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー 真核細胞ベースの遺伝子相互作用クローニング
AU5143099A (en) * 1998-07-30 2000-02-21 Universite De Montreal Protein fragment complementation assays for the detection of biological or drug interactions
ES2305093T3 (es) * 2000-06-13 2008-11-01 Bayer Healthcare Ag Regulacion de la serina proteasa transmembrana humana.
AU2067202A (en) 2000-11-14 2002-05-27 Vlaams Interuniv Inst Biotech Functional fragment of the lectine receptor
CA2437265A1 (en) 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified leptin with reduced immunogenicity
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist

Also Published As

Publication number Publication date
US20030100021A1 (en) 2003-05-29
CA2407872C (en) 2013-11-12
EP1283878B1 (de) 2005-07-27
WO2001090188A3 (en) 2002-06-13
US7855270B2 (en) 2010-12-21
US20100173408A1 (en) 2010-07-08
CA2407872A1 (en) 2001-11-29
AU8178401A (en) 2001-12-03
EP1612221A2 (de) 2006-01-04
WO2001090188A9 (en) 2002-09-19
DE60112282T2 (de) 2006-04-20
JP2003533998A (ja) 2003-11-18
EP1283878A2 (de) 2003-02-19
WO2001090188A2 (en) 2001-11-29
EP1612221A3 (de) 2008-07-23
JP4756813B2 (ja) 2011-08-24
US8003757B2 (en) 2011-08-23
DE60112282D1 (de) 2005-09-01
AU2001281784B2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
ATE300611T1 (de) Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen
ATE504599T1 (de) Zur aktivierung von rezeptoren fähige fusionspolypeptide
ATE373012T1 (de) An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendung
PT1133559E (pt) Receptor acoplato a proteina g orfao humano, rup3
DE602005019495D1 (de) Ligand für den Formylpeptidrezeptorähnlichen- 2 (FPRL2) G Protein gekoppelten Rezeptor und dessen Anwendung
NO2011003I1 (no) Dimensk fusjonsprotein bestående av de ligandbindende cfomener av de ekstacellulære deler av human type I interieukm-1 reseptor (IL-1R1) og IL-1 reseptor hjelpeprotein bundet (IL-I-RAcP) bundet i tinje til Fc-delen av humant IgG
DK1011704T3 (da) Tumornekrose-faktor-receptor-afledte peptid-analiger
MX2007015931A (es) Receptores de sabor dulce-umami y umami-dulce humanos quimericos.
DE602004022390D1 (de) Verbesserte fc-fusionsproteine
TNSN07040A1 (fr) Proteines de fusion de rage et methodes d'utilisation
DE60042617D1 (de) Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
DK0517895T3 (da) Kimæriske kæder til receptorforbundne signaltransduktionsveje
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
ATE308609T1 (de) Pth rezeptor und testverfahren unter verwendung desselben
DE69840303D1 (de) Neue g-protein gekoppelte rezeptorproteine
ATE462977T1 (de) Verfahren zum nachweis von autoimmunantikörpern gegen den tsh-rezeptor und neue tsh- rezeptorchimären
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
WO2001085930A3 (en) Methods and compounds for modulating melanocortin receptor ligand binding and activity
DE69417223D1 (de) Ein menschlicher t-zell rezeptor der protein g-gekoppelte rezeptor familie
Lodge et al. Identification and characterization of CEPU-Se—a secreted isoform of the IgLON family protein, CEPU-1
SE9701010D0 (sv) Antibody
DE60329116D1 (de) Herstellung von homotrimeren fusionsproteinen
ATE491030T1 (de) Rekombinante expression von rubella e1 hüllenproteinvarianten als chaperon- fusionsproteine und seine verwendung zum nachweis von anti-rubella antikörper
DK1317564T3 (da) Screeningsfremgangsmåder til at identificere G-proteiner og andre forbindelser, som modulerer phosphodiesterase (PDE)-aktiviteten
EP1588171A2 (de) Verbessertes verfahren zum screenen mit beta-arrestin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1283878

Country of ref document: EP